Funding
Series D · Biotech

CellCentric raises $220M Series D

CellCentric raised $220 million in Series D financing announced in May.

Updated Oct 16, 2026By RoundOS Funding desk

Venrock Healthcare Capital Partners, Fidelity Management & Research Company, Sofinnova Partners, HBM Healthcare, RA Capital Management, Forbion, Pfizer, Avego BioScience Capital and American Cancer Society BrightEdge are among its backers.

The company develops inobrodib, an oral p300/CBP inhibitor for relapsed or refractory multiple myeloma.

Funding history

Series D · This round$220M

Sources

  1. CellCentricprojectstartups.com
  2. businesswire.com

Similar rounds

All Biotech rounds →
Guoke Brain-Computer

Beijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.

UndisclosedSeed · Oct 23, 2026
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026

Related